Plain-English translation of NCT06532890 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying blood markers called microRNAs in children who have recently received a heart transplant. The goal is to create a simple blood test that can help doctors know whether a child is taking the right amount of anti-rejection medicine — not too much (which increases infection risk) and not too little (which increases rejection risk).
After a heart transplant, children must take medicines to prevent their body from rejecting the new heart, but finding the right dose is challenging. Currently, doctors don't have a good way to tell if a child is taking too much or too little medicine without invasive procedures. This study aims to solve that problem with a non-invasive blood test.
You likely qualify if…
You likely don't qualify if…
You will continue receiving your normal care and visits at your transplant center for 24 months. During this time, research staff will collect blood samples at scheduled intervals and whenever you experience a significant event (like infection or rejection concerns). You will also provide information about your medical history, current medications, and other health data — all of which helps researchers understand how the blood markers relate to your transplant health.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States